The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Olmesartan /Amlodipine Mylan 40 mg/ 5 mg film coated tablets



McDermott Laboratories Ltd., T/A Gerard LaboratoriesPA0577/185/002

Main Information

Trade NameOlmesartan /Amlodipine Mylan 40 mg/ 5 mg film coated tablets
Active SubstancesOlmesartan medoxomil
Amlodpine besilate
Dosage FormFilm-coated tablet
Licence HolderMcDermott Laboratories Ltd., T/A Gerard Laboratories
Licence NumberPA0577/185/002

Group Information

ATC CodeC09DB Angiotensin II antagonists and calcium channel blockers
C09DB02 olmesartan medoxomil and amlodipine

Status

License statusAuthorised
Licence Issued18/05/2018
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back